Dynamic Risk Group Analysis and Staging for Differentiated Thyroid Cancer

[1]  I. Ganly,et al.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[2]  R. Peeters,et al.  Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[3]  D. Roshan,et al.  An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma , 2018, The Journal of clinical endocrinology and metabolism.

[4]  Dong Jin Lee,et al.  The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis , 2018, World Journal of Surgery.

[5]  L. Boucai,et al.  Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence , 2018, The Journal of clinical endocrinology and metabolism.

[6]  C. Benbassat,et al.  Reassessment of Differentiated Thyroid Cancer Patients Using the Eighth TNM/AJCC Classification System: A Comparative Study. , 2018, Thyroid : official journal of the American Thyroid Association.

[7]  S. Roman,et al.  Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. , 2017, Thyroid : official journal of the American Thyroid Association.

[8]  Jee Soo Kim,et al.  Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. , 2017, Oral oncology.

[9]  J. Shah,et al.  Thyroid – Differentiated and Anaplastic Carcinoma , 2017 .

[10]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  R. Tuttle,et al.  Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. , 2013, Thyroid : official journal of the American Thyroid Association.

[12]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[13]  F. Pacini,et al.  The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma , 2011, Journal of endocrinological investigation.

[14]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[15]  Kwang-Yoon Jung,et al.  Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.

[16]  Mark Dowar,et al.  Influence of age and primary tumor size on the risk for residual/recurrent well‐differentiated thyroid carcinoma , 2009, Head & neck.

[17]  Tuttle Rm.  Risk-Adapted Management of Thyroid Cancer , 2008 .

[18]  S. Filetti,et al.  Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. , 2008, Thyroid : official journal of the American Thyroid Association.

[19]  R. Tuttle,et al.  Follow up approaches in thyroid cancer: a risk adapted paradigm. , 2008, Endocrinology and metabolism clinics of North America.

[20]  T. Pilli,et al.  Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  R. Tuttle,et al.  Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.

[22]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[23]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[24]  R. Kloos,et al.  A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  Sebastiano Filetti,et al.  Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  P. Arveux,et al.  Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  E. Vignali,et al.  Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens , 2003, Annals of Internal Medicine.

[28]  A. Pinchera,et al.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[30]  S. Larson,et al.  Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.

[31]  C. Spencer.  Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[32]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[33]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.